Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Clinical Psychopharmacology and Neuroscience ; : 559-563, 2019.
Article in English | WPRIM | ID: wpr-763562

ABSTRACT

Schizophrenic patients resistant to antipsychotics are diagnosed as having treatment-refractory schizophrenia, and they are treated with clozapine. However, clozapine is sometimes combined with electroconvulsive therapy (ECT) if clozapine monotherapy fails. In this report, a severe treatment-refractory schizophrenic patient who did not respond to clozapine even with ECT, but who recovered with asenapine monotherapy, is presented. Asenapine, considered a serotonin spectrum dopamine modulator, is a new atypical antipsychotic with unique pharmacological features that is used not only for schizophrenia, but also for bipolar disorder. The unique features of asenapine may be effective for some treatment-refractory schizophrenic patients.


Subject(s)
Humans , Antipsychotic Agents , Bipolar Disorder , Clozapine , Dopamine , Electroconvulsive Therapy , Recurrence , Schizophrenia , Serotonin , Suicide
SELECTION OF CITATIONS
SEARCH DETAIL